December 29, 2025
Indian Immunologicals Limited (IIL), a major vaccine manufacturer in the country, has stated that a counterfeit batch of its human anti-rabies vaccine, Abhayrab, is no longer available in the market. The clarification follows a recent advisory issued by Australian health authorities cautioning about the circulation of a fake batch in India since November 1, 2023.
Responding to the advisory, IIL described it as overly cautious and said the issue had already been identified and addressed. In an official statement released on Saturday (December 27, 2025), the company said the counterfeit involved Abhayrab batch number KA24014, manufactured in March 2024 with an expiry date of February 2027. The anomaly was detected by early January 2025, after which swift action was taken, it added.
Earlier, the Australian Technical Advisory Group on Immunisation had warned that travellers vaccinated with Abhayrab in India after November 1, 2023, should treat the vaccination as invalid and begin a fresh immunisation schedule.
Rabies, a viral disease transmitted from animals to humans, affects the central nervous system and is almost always fatal once symptoms appear. However, timely vaccination following exposure can effectively prevent the disease.
IIL highlighted that it has been producing the anti-rabies vaccine since 2000 and has supplied over 210 million doses across India and more than 40 countries, maintaining around a 40 per cent share of the domestic market.
According to the company, the counterfeit was limited to a single batch and involved a packaging irregularity. Upon detection, IIL immediately informed regulatory authorities and law enforcement agencies, filed a formal complaint and coordinated with officials to prevent further circulation. The company reiterated that this was an isolated incident and that the fake stock has since been removed from the supply chain.
Reassuring doctors and the public, IIL stressed that all vaccines manufactured in India undergo mandatory testing and release by the Central Drugs Laboratory before being made available for use.
“Vaccines supplied through government channels and authorised distributors continue to be safe and meet quality standards,” said Sunil Tiwari, vice-president and head of quality management at IIL. He added that Abhayrab is produced in compliance with World Health Organization Good Manufacturing Practices and relevant pharmacopeial norms.
The company further noted that the vaccine is approved for both pre-exposure and post-exposure prophylaxis against rabies and is supplied to public health systems as well as private healthcare providers. Each batch, it said, is cleared by the National Control Laboratory, which is WHO-Geneva pre-qualified under India’s National Regulatory Authority.
Meanwhile, earlier this month, the US Centers for Disease Control and Prevention issued travel health alerts for India and Haiti after cases of rabies were reported among travellers returning from these countries. The advisory urged travellers to avoid contact with dogs, cats and wild animals.
Source: The Hindu